Evaluation of the Duration of Bupivacaine Spinal Block in Orthopedic Procedures With and Without Epinephrine Wash

Not Applicable

Completed

• Conditions: Arthropathy of Hip; Arthropathy of Knee
• Interventions: Drug: Bupivacaine Only; Drug: EPI25; Drug: EPI50 group; Drug: EPI75 group; Drug: EPI100 group

• Registration Number: NCT02619409
• Lead Sponsor: Medical University of South Carolina

Brief Summary

Bupivacaine spinal is commonly performed as the primary anesthetic for orthopedic procedures. In some cases the duration of the block is inadequate. An epinephrine wash is sometimes performed to prolong the duration of the block. The epinephrine wash may prolong the duration of the block, and if it does, to what extent?

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2015-11-30
• Study First Submitted QC: 2015-12-01
• Study First Posted: 2015-12-02
• Study Start: 2016-02-11
• Primary Completion: 2016-10-20
• Study Completion: 2016-10-20
• Results First Submitted: 2018-02-28
• Results First Submitted QC: 2018-06-19
• Results First Posted: 2018-07-17
• Status Verified: 2023-05
• Last Update Submitted: 2023-05-12
• Last Update Posted: 2023-06-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• 18 years of age or older
• Patients scheduled for total hip or knee replacement

Read More

Exclusion Criteria

• Patients taking anticoagulation
• Infection at or near the intended needle insertion site
• Patients with sacral decubitus ulcer at or near the intended needle insertion site aortic stenosis
• Complex spine anatomy
• ASA class greater than III
• Failed SAB as determined by the staff anesthesiologist

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Bupivacaine Only	Bupivacaine Only	The bupivacaine only group will receive bupivacaine 0.5% 3cc plus sterile saline 0.1cc.
EPI25 group	EPI25	The EPI25 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.025cc, and sterile saline 0.075cc.
EPI50 group	EPI50 group	The EPI50 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.05cc, and sterile saline 0.05cc.
EPI75 group	EPI75 group	The EPI75 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.075 cc, and sterile saline 0.025%.
EPI100 group	EPI100 group	The EPI100 group will receive bupivacaine 0.5% 3cc, and epinephrine 1:1000 0.1cc

Primary Outcome Measures

Name	Time	Method
Duration of Sensory Block	12 hours	Duration of the sensory block at the T12 dermatome will be assessed in the post operative phase
Duration of Motor Block	12 hours	(hip felxion) of the non operative leg

Trial Locations

Locations (1)

Medical University of South Carolina; 🇺🇸 Charleston, South Carolina, United States